PORTLAND, Ore.--(BUSINESS WIRE)--HemCon Medical Technologies, Inc. is pleased to announce that its partner in Japan, Zeria Pharmaceutical Co., Ltd., has obtained regulatory clearance from the Ministry of Health Labor and Welfare for the HemCon® Bandage, GuardaCare™ and ChitoGauze™ product lines and will begin sales through Zeria’s subsidiary, Zeria Shoji Co., Ltd.
In accordance with the agreement signed between HemCon and Zeria in April of last year, other products in the HemCon family will be added to Zeria’s offerings in the coming months, with various distribution and sales mechanisms to be employed.
“We are very pleased with the progress Zeria has made in getting our products approved and launched for sale in Japan,” said Nick Hart, HemCon’s newly appointed President. “We look forward to additional product introductions and continuing to expand on this key partnership in Japan,” added Hart.
HemCon Medical Technologies Inc. (www.hemcon.com) founded in 2001, is a leading global developer of advanced medical products designed to improve the standard of patient care. The company develops, manufactures, and markets innovative technologies to control bleeding and infection. HemCon products are designed for use by military and civilian medical professionals and are changing wound care best practices in hospital, dental and clinical settings. In addition, HemCon continues to develop unique, life-saving medical advances including Lyophilized Human Plasma. HemCon is headquartered in Portland, Ore., with additional commercial operations in Ireland and the Czech Republic.